What is the impact factor of Molecular Psychiatry?

Molecular Psychiatry has an impact factor of 11.0 (2024). This places it among the top-tier journals in its field with Molecular Psychiatry sits at the intersection of psychiatry and molecular neuroscience, but that's not the full picture.

How long does Molecular Psychiatry take to review?

Molecular Psychiatry typically takes 45-60 days to first decision. The full review process involves 6 main stages: pre-submission inquiry (optional but recommended), initial manuscript submission, and peer review.

All Journal Guides

Journal Guide

Molecular Psychiatry Impact Factor 11.0: Publishing Guide

Q: What is the acceptance rate of Molecular Psychiatry?

Molecular Psychiatry has an acceptance rate of ~12%. A common reason for rejection is relying on candidate gene studies without genomic context. The candidate gene era in psychiatric genetics is over. We've learned that most candidate gene findings from the 2000s were false positives driven by small samples and publication bias. If you're still studying COMT, BDNF, or 5-HTTLPR without embedding your work in GWAS context, you'll get desk-rejected. The only exception is if you're doing deep mechanistic work on a gene that has survived genome-wide significance in modern studies.

Q: Is Molecular Psychiatry peer reviewed?

Yes, Molecular Psychiatry is fully peer reviewed. All submissions undergo rigorous peer review by Expect three reviewers, typically including a geneticist, a psychiatrist, and a basic neuroscientist. Reviews are thorough - prepare for requests for additional experiments, larger samples, or replication in independent datasets. The journal uses single-blind review..

Q: What does Molecular Psychiatry look for in submissions?

Mechanistic depth over surface associations: A GWAS finding alone won't cut it here unless it's the largest ever for that condition. What editors want is the next step - you've found the association, now show what it does. That might mean iPSC-derived neurons, brain organoids, or mouse models with humanized variants. Papers that stop at 'variant X is associated with disorder Y' get sent to specialty genetics journals instead.

Q: What should I know before submitting to Molecular Psychiatry?

Include sex-stratified analyses even if not your main focus. Psychiatric disorders show strong sex differences in prevalence and presentation, and reviewers will ask about this. You don't need to make it your main story, but showing that your effects hold or differ by sex demonstrates rigor and often reveals additional biology worth discussing.

Molecular Psychiatry wants papers connecting genes, cells, or circuits to mental illness in ways that matter for treatment. That is the bar. Not interesting biology, but biology with a clear psychiatric mechanism.

11.0

Impact Factor (2024)

~12%

Acceptance Rate

45-60 days to first decision

Time to First Decision

What Molecular Psychiatry Publishes

Molecular Psychiatry sits at the intersection of psychiatry and molecular neuroscience, but that's not the full picture. Editors want papers that move beyond correlation to mechanism - showing not just that gene X is associated with schizophrenia, but how that association plays out at the cellular or circuit level. The journal's sweet spot is translational work that bridges human genetics or clinical findings with model systems that explain the biology. They're particularly interested in polygenic risk, epigenetics, neuroinflammation, and anything that suggests new therapeutic targets. Single-modality studies can succeed, but you'll need exceptional sample sizes or methodological innovation to stand out.

Genome-wide association studies and polygenic risk scores for psychiatric disorders, especially those with functional follow-up that explains biological pathways.
Postmortem brain studies that integrate transcriptomics, proteomics, or epigenetics with clinical phenotype data from well-characterized patient cohorts.
Preclinical models that directly test mechanisms suggested by human genetic findings, not just face-valid behavioral models of depression or anxiety.
Neuroimaging genetics that goes beyond showing brain differences to demonstrating how specific variants alter circuit function.
Treatment mechanism studies showing why drugs work or don't work at the molecular level, particularly pharmacogenomics and biomarker research.

Editor Insight

“I see about 50 submissions a week, and most don't make it past my initial screen. What kills papers for us isn't usually bad science - it's mismatch with what we're trying to publish. We want mechanism, not just association. I'll desk-reject a well-conducted GWAS if there's no functional follow-up, because those papers belong in genetics journals, not here. What gets me excited is when authors connect levels - they've got the human genetics, they've validated in tissue, and they've shown the biology in a model system. That's when I know it's worth sending to reviewers. We also value honest uncertainty. If your mechanism is provisional or your replication is partial, say so. Reviewers can smell overclaiming, and they'll punish it. The papers that sail through review are the ones that are ambitious in scope but modest in claims. One more thing - cover letters matter here. Tell me why this work matters for patients, not just for science. That's what Molecular Psychiatry is ultimately about.”

What Molecular Psychiatry Editors Look For

Mechanistic depth over surface associations

A GWAS finding alone won't cut it here unless it's the largest ever for that condition. What editors want is the next step - you've found the association, now show what it does. That might mean iPSC-derived neurons, brain organoids, or mouse models with humanized variants. Papers that stop at 'variant X is associated with disorder Y' get sent to specialty genetics journals instead.

Clinical relevance that's explicit, not assumed

You can't just study a gene linked to schizophrenia and assume the clinical relevance is obvious. Spell out how your findings might change diagnosis, treatment selection, or drug development. The best papers here include a section on therapeutic implications that isn't hand-waving - it's specific about what your mechanism suggests for intervention.

Sample sizes that match the effect you're claiming

Psychiatric genetics has been burned by underpowered studies that don't replicate. If you're doing human genetics, you need thousands of subjects. If you're doing postmortem brain work, you need at least 30-50 per group and ideally independent replication cohorts. Small-sample mechanistic studies are fine, but only if they're testing hypotheses generated by large human datasets.

Multi-level integration across scales

The papers that really excite editors here connect multiple levels of analysis. Start with patient genetics, validate in postmortem tissue, model in cells or animals, and show behavioral or physiological consequences. You don't need all four, but papers with two or three levels of evidence consistently outperform single-modality work.

Negative results that are definitive

Surprisingly, Molecular Psychiatry will publish well-powered negative results because the field has so many false positives. If you've run a large replication study and a previously reported finding doesn't hold up, that's publishable - but your study needs to be at least as well-powered as the original. They won't publish a 200-subject failure to replicate a 10,000-subject finding.

Why Papers Get Rejected

These patterns appear repeatedly in manuscripts that don't make it past Molecular Psychiatry's editorial review:

Relying on candidate gene studies without genomic context

The candidate gene era in psychiatric genetics is over. We've learned that most candidate gene findings from the 2000s were false positives driven by small samples and publication bias. If you're still studying COMT, BDNF, or 5-HTTLPR without embedding your work in GWAS context, you'll get desk-rejected. The only exception is if you're doing deep mechanistic work on a gene that has survived genome-wide significance in modern studies.

Overstating translational potential of rodent behavioral models

Editors here are deeply skeptical of claims like 'this mouse shows depression-like behavior' because they know these models have led psychiatry astray for decades. If you're using rodent models, be explicit about their limitations and don't claim you've modeled the human disorder. Focus instead on specific, measurable circuit or molecular changes that can be validated in human tissue.

Ignoring medication confounds in patient studies

Almost every psychiatric patient is on medication, and those drugs have molecular effects. If you're comparing patient and control brain tissue or blood, you must address whether your findings reflect disease biology or drug exposure. The best papers include medication-free subjects, correlate with drug exposure, or validate in drug-naive animal models.

Focusing on a single brain region without justification

Psychiatric disorders are circuit disorders, not regional ones. If you've only looked at prefrontal cortex or hippocampus, reviewers will ask why you didn't examine connected regions. Either provide a strong rationale for regional specificity or include multiple regions in your analysis. Cherry-picking the one region that shows your effect is a fast track to rejection.

Submitting imaging studies without molecular or genetic anchors

Pure neuroimaging papers, even with large samples, often get redirected to imaging-specific journals unless there's a molecular component. If you're doing fMRI or PET, tie it to genetics, receptor binding, or a molecular mechanism. 'Patients show altered connectivity' isn't enough for this journal - you need to explain why at the biological level.

Does your manuscript avoid these patterns?

The quick diagnostic reads your full manuscript against Molecular Psychiatry's criteria and flags the specific issues most likely to cause rejection.

Run Free Readiness Scan →

Insider Tips from Molecular Psychiatry Authors

Include sex-stratified analyses even if not your main focus

Psychiatric disorders show strong sex differences in prevalence and presentation, and reviewers will ask about this. You don't need to make it your main story, but showing that your effects hold or differ by sex demonstrates rigor and often reveals additional biology worth discussing.

Reference the PGC and other major consortia appropriately

The Psychiatric Genomics Consortium has published the definitive genetic studies for most major disorders. Your paper should cite and compare to their findings. If your results contradict PGC data, you need a very good explanation - ideally showing why your approach captures something the consortium missed.

Don't shy away from complexity in your genetic findings

Editors here understand that psychiatric genetics is messy. Pleiotropy, polygenicity, and gene-environment interactions are the norm, not exceptions. Papers that acknowledge this complexity and try to parse it are viewed more favorably than those claiming clean, simple genetic effects.

Pre-registration strengthens genetic association claims

Given the replication crisis in psychiatric genetics, pre-registered studies get extra credibility. If you've lodged your hypotheses and analysis plan on OSF or a similar platform before looking at the data, mention this prominently. It signals to reviewers that your findings aren't the result of analytic flexibility.

Your supplementary material will be scrutinized heavily

Reviewers for this journal dig deep into supplements because that's where methodological problems hide. Include full quality control metrics for your genetic data, sensitivity analyses, and negative controls. Hiding weak analyses in supplementary files doesn't work - it just annoys reviewers who find them.

The Molecular Psychiatry Submission Process

Pre-submission inquiry (optional but recommended)

5-7 days for response

For high-risk submissions, email the editorial office with a structured abstract and your key figures. They'll tell you within a week if the work fits their scope. This saves months if your topic falls outside their current interests.

Initial manuscript submission

Same day completion

Submit through the Springer Nature portal with your manuscript, figures, and supplementary files. You'll need to suggest reviewers, but don't just name friends - editors check for conflicts and obvious cronyism. Suggest people who've published similar methods but competing findings.

Editorial triage and desk decision

7-14 days

The handling editor screens for scope, novelty, and basic quality. About 40% of submissions are desk-rejected at this stage. If your paper advances to review, it's already beaten significant odds. Desk rejections come fast, usually within two weeks.

Peer review

4-6 weeks

Expect three reviewers, typically including a geneticist, a psychiatrist, and a basic neuroscientist. Reviews are thorough - prepare for requests for additional experiments, larger samples, or replication in independent datasets. The journal uses single-blind review.

Revision and response

60-120 days allowed

If invited to revise, you'll usually have 60 days for minor revisions and 90-120 days for major ones. Write a detailed point-by-point response - don't just say 'done.' Explain your reasoning even when you disagree with reviewers.

Final decision and production

2-4 weeks to online publication

After re-review, decisions are usually final. Accepted papers go through copyediting and typesetting within a few weeks. You'll receive proofs to check, and the paper goes online as an advance article before print assignment.

Molecular Psychiatry by the Numbers

Impact Factor(2024 JCR, consistently top 5 in psychiatry)	11.0
Acceptance Rate(Highly selective, especially for genetics papers)	~12%
Time to First Decision(Faster for desk rejections, longer for full review)	45-60 days
Submissions per Year(Growing annually as field expands)	~2,500
CiteScore(Scopus metric, reflecting citation velocity)	18.8
Open Access Option(Hybrid model, ~$4,500 APC for gold OA)	Available

Before you submit

Molecular Psychiatry accepts a small fraction of submissions. Make your attempt count.

The pre-submission diagnostic runs a live literature search, scores your manuscript section by section, and gives you a prioritized fix list calibrated to Molecular Psychiatry. ~30 minutes.

Run Free Readiness Scan See a sample report

Article Types

Original Article

4,000-5,000 words excluding references

Full research papers presenting new findings. These are the bread and butter of the journal, representing about 80% of published content. Must include novel data and mechanistic insight.

Review

6,000-8,000 words

Invited and submitted reviews synthesizing recent advances. Unsolicited reviews face steep odds - you need a fresh angle, not just a literature summary. Meta-analyses are considered reviews.

Immediate Communication

2,000 words maximum

Short reports of exceptional findings requiring rapid publication. Reserved for truly time-sensitive results like COVID-19 mental health impacts or breakthrough treatment mechanisms.

Correspondence

1,000 words

Brief letters responding to published articles or presenting small datasets that add to existing literature. Good for replication studies or methodological comments.

Perspective

3,000 words

Opinion pieces on emerging issues in molecular psychiatry. Usually invited, but strong proposals from established researchers are considered. Must present a clear argument, not just summarize the field.

Landmark Molecular Psychiatry Papers

Papers that defined fields and changed science:

Sullivan et al., 2012 - Genetic architecture of psychiatric disorders reveals shared biology across schizophrenia, bipolar disorder, autism, ADHD, and major depression
Christoforou et al., 2011 - Found convergence of linkage, association and GWAS findings for psychiatric disorders
Myers-Schulz et al., 2012 - Functional anatomy of ventromedial prefrontal cortex in emotion regulation and psychiatric disorders
Khandaker et al., 2014 - Demonstrated that childhood infection and inflammation increase risk for adult psychosis through longitudinal cohort analysis
Sullivan et al., 2018 - Published the first large-scale GWAS of major depression identifying genetic risk loci

Preparing a Molecular Psychiatry Submission?

Get pre-submission feedback from reviewers who've published in Molecular Psychiatry and know exactly what editors look for.

Run Free Readiness Scan

Need expert depth? Human review from $1,000

NDA-protected

Confidential

Primary Fields

Psychiatric genetics and genomicsSchizophrenia and psychosis biologyMood disorder mechanismsNeuroinflammation and immune psychiatryEpigenetics of mental illnessPharmacogenomics and treatment responseNeurodevelopmental disorder biologyAddiction and substance use mechanismsPTSD and stress disorder geneticsPolygenic risk and cross-disorder genetics

Related Journal Guides

Publishing in JAMA

All journal guides

All articles

Ready to submit to Molecular Psychiatry?

A desk rejection costs months. Get expert feedback before you submit, from scientists who know exactly what Molecular Psychiatry editors look for.

Need field-expert depth? Human review from $1,000